Study design (if review, criteria of inclusion for studies)
Pilot, open-label, randomized crossover trial
23 participants with CF and severe lung disease.
Nasal high-flow therapy (NHFT). Participants completed two treadmill walking test (TWT) with and without NHFT at 24-48 h interval.
Primary outcome was trial feasibility, and exploratory outcomes were TWT distance (TWTD), SpO(2), transcutaneous CO(2), dyspnoea and comfort.
Recruitment rate was 2.4 subjects/month with 1.3:1 screening-to-randomization ratio. No adverse events caused by NHFT were observed. Tolerability was good and data completion rate was 100%. Twenty subjects (91%) were included in the exploratory study. Mean difference in TWTD on NHFT was 19 m (95% CI [4.8 - 33.1]). S(p)O(2) was similar, but respiratory rate and mean tcCO(2) were lower on NHFT (mean difference = -3.9 breaths/min 95% CI [-5.9 - -1.9] and -0.22 kPa 95% CI [-0.4 - 0.04]). NHFT reduced exercise-induced dyspnoea and discomfort.
Trials using NHFT in patients with CF during exercise are feasible. NHFT appears to improve walking distance, control respiratory rate, CO(2), dyspnoea and improve comfort. A larger trial with a longer intervention is feasible and warranted to confirm the impact of NHFT in training programmes for patients with CF.